Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings (NQ: BPTH )

2.940 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.940
Bid (Size) 1.180 (2)
Ask (Size) 3.160 (1)
Prev. Close 2.940
Today's Range 2.940 - 2.940
52wk Range 0.3200 - 7.500
Shares Outstanding 678,795
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bio-Path Holdings Expands Global Patent Portfolio
Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Provides 2024 Clinical and Operational Update
Clinical Advances Across Multiple Programs with Several Milestones 
From Bio-Path Holdings, Inc.
Via GlobeNewswire

Performance

YTD
+496.95%
+496.95%
1 Month
-39.51%
-39.51%
3 Month
+539.13%
+539.13%
6 Month
+332.29%
+332.29%
1 Year
+111.53%
+111.53%

More News

Read More
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
Via Newsfile
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Bio-Path Holdings's Earnings: A Preview
Via Benzinga
Bio-Path Hldgs: Q3 Earnings Insights
Via Benzinga
Why Bio-Path Holdings Shares Are Falling Today
Via Benzinga
Bio-Path Holdings Reports Full Year 2023 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Earnings Scheduled For March 8, 2024
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Preview: Bio-Path Holdings's Earnings
Via Benzinga
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
From Bio-Path Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
From Bio-Path Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Why UP Fintech Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
From Bio-Path Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.